Literature DB >> 29875421

A cross-sectional quantitative analysis of the natural history of free sialic acid storage disease-an ultra-orphan multisystemic lysosomal storage disorder.

Matthias Zielonka1,2,3, Sven F Garbade4,5, Stefan Kölker4,5, Georg F Hoffmann4,5, Markus Ries4,5.   

Abstract

PURPOSE: Quantitative definition of the natural history of free sialic acid storage disease (SASD, OMIM 604369), an orphan disorder due to the deficiency of the proton-driven carrier SLC17A5.
METHODS: Analysis of published cases with SASD (N = 116) respecting STROBE criteria. MAIN OUTCOME PARAMETERS: survival and diagnostic delay. Phenotype, phenotype-biomarker associations, and geographical patient distribution were explored.
RESULTS: Median age at disease onset was 0.17 years. Median age at diagnosis was 3 years with a median diagnostic delay of 2.5 years. Median survival was 11 years. The biochemical phenotype clearly predicted the disease course: patients with a urinary free sialic acid excretion below 6.37-fold or an intracellular free sialic acid storage in fibroblasts below 7.37-fold of the mean of normal survived longer than patients with biochemical values above these thresholds. Cluster analysis of disease features suggested a continuous phenotypic spectrum. Patient distribution was panethnic.
CONCLUSION: Combination of neurologic symptoms, visceromegaly, and dysmorphic features and/or nonimmune hydrops fetalis should prompt specific tests for SASD, reducing diagnostic delay. The present quantitative data inform clinical studies and may stimulate and accelerate development of specific therapies. Biomarker-phenotype association is particularly important for both counseling parents and study design.

Entities:  

Keywords:  Drug development; Natural history; Orphan disease; SLC17A5; Sialic acid storage disease

Mesh:

Substances:

Year:  2018        PMID: 29875421     DOI: 10.1038/s41436-018-0051-3

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  6 in total

1.  Lysosomal storage disease spectrum in nonimmune hydrops fetalis: a retrospective case control study.

Authors:  Huda B Al-Kouatly; Laura Felder; Mona M Makhamreh; Stephanie L Kass; Neeta L Vora; Vincenzo Berghella; Seth Berger; David A Wenger; Paola Luzi
Journal:  Prenat Diagn       Date:  2020-03-20       Impact factor: 3.050

Review 2.  Free sialic acid storage disorder: Progress and promise.

Authors:  Marjan Huizing; Mary E Hackbarth; David R Adams; Melissa Wasserstein; Marc C Patterson; Steven U Walkley; William A Gahl
Journal:  Neurosci Lett       Date:  2021-04-20       Impact factor: 3.046

Review 3.  Lysosomes as a therapeutic target.

Authors:  Srinivasa Reddy Bonam; Fengjuan Wang; Sylviane Muller
Journal:  Nat Rev Drug Discov       Date:  2019-09-02       Impact factor: 84.694

4.  Prenatal hydrops fetalis associated with infantile free sialic acid storage disease due to a novel homozygous deletion in the SLC17A5 gene.

Authors:  Afia Hasnain; Sherri Burnett; Ronald Agatep; Elizabeth Spriggs; Bernard Chodirker; Aizeddin Aziz A Mhanni
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-10-19

5.  Quantitative analysis of the natural history of prolidase deficiency: description of 17 families and systematic review of published cases.

Authors:  Francis Rossignol; Marvid S Duarte Moreno; Carlos R Ferreira; Manuel Schiff; Jean-François Benoist; Manfred Boehm; Emmanuelle Bourrat; Aline Cano; Brigitte Chabrol; Claudine Cosson; José Luís Dapena Díaz; Arthur D'Harlingue; David Dimmock; Alexandra F Freeman; María Tallón García; Cheryl Garganta; Tobias Goerge; Sara S Halbach; Jan de Laffolie; Christina T Lam; Ludovic Martin; Esmeralda Martins; Andrea Meinhardt; Isabelle Melki; Amanda K Ombrello; Noémie Pérez; Dulce Quelhas; Anna Scott; Anne M Slavotinek; Ana Rita Soares; Sarah L Stein; Kira Süßmuth; Jenny Thies
Journal:  Genet Med       Date:  2021-05-26       Impact factor: 8.822

6.  FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.

Authors:  Sven F Garbade; Matthias Zielonka; Konstantin Mechler; Stefan Kölker; Georg F Hoffmann; Christian Staufner; Eugen Mengel; Markus Ries
Journal:  PLoS One       Date:  2020-04-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.